Evidence of Rising Neurological Mortality and Examining Multiple-Interactive Environmental Causes in the 21stCentury

Main Article Content

Colin Pritchard Anne Silk Lars Hansen


Aims: To examine whether increased neurological deaths during 21st Century are predominately due to elderly demographics, or major influences of interactive-multiple environmental contributory factors? We examine WHO Early-Adult-Deaths (55-74yearolds), which is below Western life-expectancy, and total Age-Standardised-Death-Rates (ASDR) controlled by age, sex, and population, to challenge the demographic assumption.


Based upon WHO latest global neurological mortality categories, Nervous-Disease-Deaths and Alzheimer’s & Other Dementias, which provides the Combined Neurological Death, rates per million (pm), for the twenty-one West-Developed-Nations (WDN) over the period.

Early-Adult-Death rates based upon numbers of deaths, divided by 55-74 population and WHO total ASDR during the 21st Century. Increases between Over 75’s population and Over 75’s neurological mortality is compared using Odds Ratios. Numbers of deaths are indicative of family and services pressures.

Results: Every country’s 55-74yearolds Nervous-Disease-Deaths rates were higher than Alzheimer’s & Dementia Deaths, ten countries Nervous-Disease-Deaths rose higher than Alzheimer’s & Dementias during Century.

Highest Combined Deaths and increases were Finland 1006 per million (pm) up 44%, USA 710pm, rose 39% and UK 653pm a rise of 32%, countries average of 25%, though Belgium, Canada and France rates fell.

Highest ASDR were Finland 973pm, up 104%, USA 592pm, rose 76%, UK 553pm, increase 170%. Lowest were Japan 112pm, yet up 90%, Greece 184pm, rose 64% and Austria 214pm increased 102%, average nation’s 62%.

Belgium at 387pm up 34%, Canada 401pm, increased 13% and France ASDR 336pm up 11%.

Population compared with total neurological amongst Early-Adult-Deaths and Over 75’s, ratios of change, were respectively 1:1.34 and 1:2.21, yielding an Odds ratios of 1:1.65

French total neurological numbers were 40,594 rose to 71,543, up 76%, UK 24,601 to 103,550 increased 321% and the USA 174,708 to 436,438 rising 150%.

Discussion: We reject the hypothesis that neurological increases were mainly dues to demographics. Our results support by new studies across the continents, with their findings of significant causal multiple-interactive-environmental pollutants, including, endocrine disruptive chemicals, air pollution, organophosphates, plastics, petrochemicals, impact of low ubiquitous prolonged electro-magnetism, etc, associated with neuro-degenerative disease, especially Early-Onset-Dementia, below Western life-expectancy.

Conclusions: Governments should seek urgent research to explain this new epidemic.

Article Details

How to Cite
PRITCHARD, Colin; SILK, Anne; HANSEN, Lars. Evidence of Rising Neurological Mortality and Examining Multiple-Interactive Environmental Causes in the 21stCentury. Medical Research Archives, [S.l.], v. 10, n. 9, sep. 2022. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/3126>. Date accessed: 23 feb. 2024. doi: https://doi.org/10.18103/mra.v10i9.3126.
Research Articles


1.Pritchard C, Baldwin D & Mayers A (2004) Changing patterns of adult [45-74 years] neurological deaths in the major Western world countries 1979-97 Public Health 116: 1-16.

2.Goldacre MJ, Duncan M, Griffith M, Turner MR (2010) Trends in death certification for multiple sclerosis, motor neuron disease, Parkinson’s disease and epilepsy in English populations 1979-2006. J Neurol. 257: 706-715.

3.ONS (2022) Dementia and Alzheimer’s disease deaths including comorbidities, England & Wales: 2019 registrations. Deaths registered in 2019 in England and Wales due to dementia and Alzheimer's disease, by sex, age group, ethnicity, region, and place of occurrence. Includes analysis of comorbidities.www.ons.gov.uk.

4.Riggs JE, Schochet SS Jr (1992) Rising mortality due to Parkinson’s disease and amyotrophic lateral sclerosis: a manifestation of the competitive nature of human mortality. J Clin Epidemiol. 45: 1007-1012.

5. Easton DM. Gompertzian growth and decay: a powerful descriptive tool for neuroscience. Physiol Behav. 2005;86:407-414.

6.Pritchard C, Mayers A, Baldwin DS (2013) Changing patterns of neurological mortality in the 10 major developed countries 1979-2010. Public Health, 127, 357-68.

7.Pritchard C, Rosenorn-Lanng E, Silk A, Hansen L (2017) International and USA Population-Based Study Comparing Adult [55-74] Neurological Deaths with Control Cancer and Circulatory Disease Deaths 1989-2014. Acta Neurologica Scandinavia, 136; 698-707. doi:10.1111/ane.12789

8.Scheltens P, Strooper D B, Kiipelto M, Holstege H, Chetelat G , Teunissen CE, Alheimer’s Disease. Lancet, 2021. Seminar. 397: 1577-1590.

9.Nilsson C, Lundqvist LM, Nilsson K, Santillio A, Vestberg S. Age- related incidence and family history in frontotemporal dementia: data from the Swedish Dementia Registry. PLoS One. 2014;9:90-94.

10.Rantalainen V, Lahti J, Henriksson M, Kajantie E, Eriksson JG, Räikkönen K.
Cognitive ability in young adulthood predicts risk of early-onset dementia in Finnish men. Neurology. 2018 Jul 10;91(2):e171-e179. doi: 10.1212 /WNL. 0000000000005757.

11.WHO (2020) Annual mortality by causes, sex, and age: who.int/mortality/stastistics.dpms.

12. Altman DG, Machin D, Bryant TN & Gardner MJ (2002) Statistics with Confidence. 2nd Edition, London. BMJ Books

13. www. https// Canada.gov. Dept Immigration, Refugees & Citizenship. 20202.

14. Pritchard C & Silk A (2018) Patient’s occupation, electric & head trauma in a cohort of 88 Multiple System Atrophy patients compared with the general population: a hypothesis stimulating pilot study. Journal Neurology & Stroke, 8, 3; 178-183.

15.Batla A, De Pablo-Fernandez E, Erro R, Reich M, Calandra-Buonaura G, Barbosa P, Balint B, Ling H, Islam S, Cortelli P, Volkmann J, Quinn N, Holton JL, Warner TT, Bhatia KP. Young-onset multiple system atrophy: Clinical and pathological features. Mov Disord. 2018.33:1099-1107.

16. Mendez MF. Early-onset Alzheimer Disease and Its Variants. Continuum (Minneap Minn). 2019. 25(1):34-51.

17.Velayudhan L, Baillon S, Daby L, Suntharamoorthy P, Kablan A, Tromans S, Lindesay J. Predictors of Disease Progression in Early-Onset Alzheimer's Dementia: A Retrospective Cohort Study. J Am Med Dir Assoc. 2020. 21(11):1735-1739

18.Spina S, La Joie R, Petersen C, Nolan AL, Cuevas D, Cosme C, Hepker M, Hwang JH, Miller ZA, Huang EJ, Karydas AM, Grant H, Boxer AL, Gorno-Tempini ML, Rosen HJ, Kramer JH, Miller BL, Seeley WW, Rabinovici GD, Grinberg LT. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease. Brain. 2021.144(7):2186-2198.

19.Graff-Radford J, Yong KXX, Apostolova LG, Bouwman FH, Carrillo M, Dickerson BC, Rabinovici GD, Schott JM, Jones DT, Murray ME. New insights into atypical Alzheimer's disease in the era of biomarkers. Lancet Neurol. 2021. 20(3):222-234.

20. Ayodele T, Rogaeva E, Kurup JT, Beecham G, Reitz C. Early-Onset Alzheimer's Disease: What Is Missing in Research? Curr Neurol Neurosci Rep. 2021 Jan 19;21(2):4. doi: 10.1007/s11910-020-01090-y.PMID: 33464407.

21. Perrone F, Cacace R, Van Mossevelde S, Van den Bossche T, De Deyn PP, Cras P, Engelborghs S, van der Zee J, Van Broeckhoven C. Genetic screening in early-onset dementia patients with unclear phenotype: relevance for clinical diagnosis. Neurobiol Aging. 2018 Sep;69:292.e7-292.e14. doi: 10.1016/j.neurobiolaging.2018.04.015.

22. Chiari A, Vinceti G, Adani G, Tondelli M, Galli C, Fiondella L, Costa M, Molinari MA, Filippini T, Zamboni G, Vinceti M. Epidemiology of early onset dementia and its clinical presentations in the province of Modena, Italy. Alzheimers Dement. 2021. 17 (1):81-88.

23. Strand BH, Knapskog AB, Persson K, Holt Edwin T, Bjertness E, Engedal K, Selbaek G. The Loss in Expectation of Life due to Early-Onset Mild Cognitive Impairment and Early-Onset Dementia in Norway. Dement Geriatr Cogn Disord. 2019;47(4-6):355-365

24. Barbiellini Amidei C, Fayosse A, Dumurgier J, Machado-Fragua MD, Tabak AG, van Sloten T, Kivimäki M, Dugravot A, Sabia S, Singh-Manoux A. Association Between Age at Diabetes Onset and Subsequent Risk of Dementia. JAMA. 2021 Apr 27;325(16):1640-1649.

25. Xuan M, Guan X, Gu Q, Shen Z, Yu X, Qiu T, Luo X, Song R, Jiaerken Y, Xu X, Huang P, Luo W, Zhang M. Different iron deposition patterns in early- and middle-late-onset Parkinson's disease. Parkinsonism Relat Disord. 2017 Nov;44:23-27. d

26.Li J, Wu L, Tang Y, Zhou A, Wang F, Xing Y, Jia J. Differentiation of neuropsychological features between posterior cortical atrophy and early onset Alzheimer's disease. BMC Neurol. 2018 May 10;18(1):65. doi: 10.1186/s12883-018-1068-6.

27. Qin Q, Yin Y, Wang Y, Lu Y, Tang Y, Jia J. Gene mutations associated with early onset familial Alzheimer's disease in China: An overview and current status. Mol Genet Genomic Med. 2020 Oct;8(10):e1443. doi: 10.1002/mgg3.1443.

28.Han LH, Xue YY, Zheng YC, Li XY, Lin RR, Wu ZY, Tao QQ. Genetic Analysis of Chinese Patients with Early-Onset Dementia Using Next-Generation Sequencing. Clin Interv Aging. 2020. 15:1831-1839.

29.Wang VW, Kandiah N, Lin X, Wee HL. Does health-related quality of life in Asian informal caregivers differ between early-onset dementia and late-onset dementia? Psychogeriatrics. 2020; 20(5):608-619.

30.Sanchez AM, Scharovsky D, Romano LM, et al., et al. Incidence of early- onset dementia in Mar del Plata. Neurologia. 2015;30: 77-82.

31.Santabárbara J, Gracía-Rebled AC, López-Antón R, Tomás C, Lobo E, Marcos G, Lobo A. The effect of occupation type on risk of Alzheimer's disease in men and women. Maturitas. 2019; 126:61-68.

32.Sanyal J, Banerjee TK, Rao VR. Dementia and cognitive impairment in patients with Parkinson's disease from India: a 7-year prospective study. Am J Alzheimers Dis Other Demen. 2014; 29(7):630-636.

33.Shahrizaila N, Sobue G, Kuwabara S, et al. Amyotrophic lateral sclerosis and motor neuron syndromes in Asia. J Neurol Neurosurg Psychiatry. 2016;87:821-830.

34.Uddin MS, Hasana S, Hossain MF, Islam MS, Behl T, Perveen A, Hafeez A, Ashraf GM. Molecular Genetics of Early- and Late-Onset Alzheimer's Disease. Curr Gene Ther. 2021;21(1):43-52.

35. Awata S, Edahiro A, Arai T, Ikeda M, Ikeuchi T, Kawakatsu S, Konagaya Y, Miyanaga K, Ota H, Suzuki K, Tanimukai S, Utsumi K, Kakuma T.Prevalence and subtype distribution of early-onset dementia in Japan. Psychogeriatrics. 2020; 20(6):817-823.

36.Hirano S, Sakakibara R, Komatsu N, Shimizu K, Ishikawa M, Hosoi N, Asahi T, Shuno T, Sugihara H, Kanai S, Miura N, Mochida H, Ozawa Y, Iyo M, Kuwabara S. Characteristics of Early-Onset Dementia in Chiba Prefecture, Japan: A Multi-Centre Survey. Dement Geriatr Cogn Disord. 2021;50(3):283-288.

37.Fazzo L, Binazzi A, Ferrante D, Minelli G, Consonni D, Bauleo L, Bruno C, Bugani M, De Santis M, Iavarone I, Magnani C, Romeo E, Zona A, Alessi M, Comba P, Marinaccio A. Burden of Mortality from Asbestos-Related Diseases in Italy. Int J Environ Res Public Health. 2021 Sep 23;18(19):10012. doi: 10.3390/ijerph181910012.PMID: 34639316.

38.Jayaraj RL, Rodriguez EA, Wang Y, Blocl ML. Outdoor Ambient Air Pollution and Neurodegenerative Diseases: The neuro-inflammation Hypothesis. Curr Environ Health Reports. 2017; 4:166-179.
39. Fu P & Yung KKK (2020) Air pollution and Alzheimer’s Disease: Systematic and Meta-Analysis. Journal Alzheimer’s Disease. 77: 701-714.

40.Gore AC, Krishnan K, Reilly MP. Endocrine-disrupting chemicals: Effects on neuroendocrine systems and the neurobiology of social behavior. Horm Behav. 2019;111:7-22.

41.Patisaul HB. Endocrine disrupting chemicals (EDCs) and the neuroendocrine system: Beyond estrogen, androgen, and thyroid. Adv Pharmacol. 2021;92:101-150.

42.Street ME, Audouze K, Legler J, Sone H, Palanza P. Endocrine Disrupting Chemicals: Current Understanding, New Testing Strategies and Future Research Needs. Int J Mol Sci. 2021 Jan 19;22(2):933. doi: 10.3390/ijms22020933.PMID: 33477789.

43.Ross SM, McManus IC, Harrison V, Mason O (2013) Neurobehavioral problems following low-level exposure to organophosphate pesticides: a systematic and meta-analytic review. Crit Rev Toxicol. 43: 21-44.

44.Belyaev I, Dean A, Eger H, Hubmann G, Jandrisovits R, Kern M, Kundi M, Moshammer H, Lercher P, Müller K, Oberfeld G, Ohnsorge P, Pelzmann P, Scheingraber C, Thill R.Rev. EUROPAEM EMF Guideline 2016 for the prevention, diagnosis and treatment of EMF-related health problems and illnesses. Environ Health. 2018;31(3):363-97.

45.Terzi M, Ozberk B, Deniz OG, Kaplan S. The role of electromagnetic fields in neurological disorders. J Chem Neuroanat. 2016 Sep;75(Pt B):77-84.

46.Durusoy R, Hassoy H, Özkurt A, Karababa AO. Mobile phone use, school electromagnetic field levels and related symptoms: a cross-sectional survey among 2150 high school students in Izmir. Environ Health. 2017 Jun 2;16(1):51. doi: 10.1186/s12940-017-0257-x.PMID: 28577556.

47.Pritchard C, Silk A, Hansen L (2019) Are Rises in Electro-Magnetic Field in the Human Environment, interacting with Multiple Environmental Pollutions, the Tripping Point for Increases in Neurological Deaths in the Western World? Medical Hypothesis. 127:76-83.Doi.org./10.1016j.mehy. 2019.0-018.

48. Johnansen C (2004) Electromagnetic fields and health effects – epidemiological studies of cancer, diseases of the central nervous system and arrhythmia related heart disease. Scand J Work Environ Health. Supplement 1: 1-80.

49. Villarini M, Gambelunghe A, Giustarini D, Ambrosini MV, Fatigoni C, Rossi R, Dominici L,et al. No evidence of DNA damage by co-exposure to extremely low frequency magnetic fields and aluminium on neuroblastoma cell lines. Mutat Res. 2017 Nov;823:11-21.

50.Saliev T, Mustapova Z, Kulsharova G, Bulanin D, Mikhalovsky S. Therapeutic potential of EMF for tissue engineering and wound healing. Cell Prolif. 2014. 47:485-493.

51. Guerriero F, Ricevuti G. Extremly low frequency electromagnetic fields stimulation modulates autoimmunity and immune responses: A possible immune-modulatory therapeutic effect in neurodegenerative diseases. Neural Regen Res. 2016. 11:1888-1895.

52.Chen Z, Liu H, Wang H, Wu C, Feng H, Han J. Effects of low-frequency rotary magnetic fields on advanced gastric cancer: Survival and Palliation of symptoms. J Cancer Res.(2018) 14: 815-819.

53.Cichoń N, Rzeźnicka P, Bijak M, Miller E, Miller S, Saluk J. Extremely low frequency electromagnetic field reduces oxidative stress during the rehabilitation of post-acute stroke patients. Adv Clin Exp Med. 2018 Jul 19. doi: 10.17219/acem/73699.;

54.Environmental Health Trust (2021) Takes the FCC to Court - Environmental Health Trust https://ehtrust.org/eht-takes-the-fcc-to-court.

55. www.Federal Communication Commission. All You need to Know About Electricity. 2020.

56.Kletetschka, G., Bazala, R., Takáč, M., & Svecova, E. (2021). Magnetic domains oscillation in the brain with neurodegenerative disease. Science Reports Nature Research. 11:714 | https://doi.org/10.1038/s41598-020-80212.

57. Carson R (1968) The Silent Spring. New York, Penguin.

58.Rustin, B. (1955) Speak Truth to Power. New York. American Friends Service Committee.